Biodexa Pharmaceuticals PLC
1 Caspian Point
Caspian Way
Cardiff, CF10 4DQ
United Kingdom
March 20, 2024
VIA EDGAR
Securities and Exchange Commission
Division of Corporate Finance
100 F Street, N.E.
Washington, DC 20549
Attention: Christopher Edwards
Re: | Biodexa Pharmaceuticals PLC |
Registration Statement on Form F-1 (File No. 333-278040) | |
Request for Acceleration of Effective Date |
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Biodexa Pharmaceuticals PLC hereby respectfully requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement on Form F-1 (the “Registration Statement”) and declare the Registration Statement effective as of 5:00 p.m., Eastern Time, on March 27, 2024, or as soon as practicable thereafter.
Please call Jason S. McCaffrey of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Company, at (617) 542-6000, with any comments or questions regarding the Registration Statement.
Very truly yours, | |
BIODEXA PHARMACEUTICALS PLC | |
By: /s/ Stephen Stamp | |
Name: Stephen Stamp | |
Title: Chief Executive Officer & Chief Financial Officer |
cc: | Jason S. McCaffrey, Esq., Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. |